Dr. Chi on Combinations with Androgen Deprivation Therapy for Prostate Cancer

Kim Chi, MD
Published: Friday, Jul 07, 2017



Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses combinations with androgen deprivation therapy for patients with prostate cancer.

Combining androgen depravation therapy with chemotherapy with abiraterone (Zytiga) is still an unanswered question that needs to be investigated, explains Chi. There have been some trials that have just finished accrual, such as the TITAN trial and the ENZAMET trial that have begun investigating this combination.

According to Chi, it might be possible to receive a better idea of which therapy is most beneficial for patients for patients with prostate cancer by looking at these subgroup analyses.
 
SELECTED
LANGUAGE


Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses combinations with androgen deprivation therapy for patients with prostate cancer.

Combining androgen depravation therapy with chemotherapy with abiraterone (Zytiga) is still an unanswered question that needs to be investigated, explains Chi. There have been some trials that have just finished accrual, such as the TITAN trial and the ENZAMET trial that have begun investigating this combination.

According to Chi, it might be possible to receive a better idea of which therapy is most beneficial for patients for patients with prostate cancer by looking at these subgroup analyses.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x